Onyx Liquid Embolic System (LES)
Ev3 Neurovascular · Decision date Dec 8, 2025
What did the FDA approve?
FDA records P030004/S035 as a supplement to PMA P030004, with the supplement type “Panel Track”. The recorded decision is approval, dated Dec 8, 2025.
FDA approval order statement
Onyx Liquid Embolic System (LES) is indicated for embolization of the middle meningeal artery (MMA) as an adjunct to surgery for the treatment of symptomatic subacute or chronic subdural hematoma (SDH).
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Neurology
- Decision date
- Dec 8, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P030004/S035
- Regulatory pathway
- PMA supplement
- Applicant
- Ev3 Neurovascular
- Product code
- SGU
- Decision code
- APPR
- Decision date
- Dec 8, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Neurovascular Liquid Embolic Agent.
- Applicant
- Ev3 Neurovascular
- Product code
- SGU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030004 · Original PMA
ONYX LIQUID EMBOLIC SYSTEM
P030004/S035 received
Application receipt date recorded by FDA.
P030004/S035 · FDA decision
Panel Track
P030004/S041 · Related supplement
Apollo Onyx Delivery Micro Catheter
P030004/S040 · Related supplement
Onyx Liquid Embolic System (LES)
P030004/S043 · Related supplement
Apollo Onyx Delivery Micro Catheter
P030004/S044 · Related supplement
Onyx Liquid Embolic System
P030004/S042 · Related supplement
Onyx Liquid Embolic System (LES)
P030004/S039 · Related supplement
Onyx Liquid Embolic System (Onyx LES)
Timeline entries are records held by MedtechLedger for P030004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ONYX LIQUID EMBOLIC SYSTEMP030004 | Ev3 Neurovascular | PMA approval | Jul 21, 2005 | FDA |
Apollo Onyx Delivery Micro CatheterP030004/S041 | Ev3 Neurovascular | PMA supplement | Apr 9, 2026 | FDA |
Onyx Liquid Embolic System (LES)P030004/S040 | Ev3 Neurovascular | PMA supplement | Apr 29, 2026 | FDA |
Apollo Onyx Delivery Micro CatheterP030004/S043 | Ev3 Neurovascular | PMA supplement | May 26, 2026 | FDA |
Onyx Liquid Embolic SystemP030004/S044 | Ev3 Neurovascular | PMA supplement | Jul 21, 2026 | FDA |
Onyx Liquid Embolic System (LES)P030004/S042 | Ev3 Neurovascular | PMA supplement | Aug 5, 2026 | FDA |
Onyx Liquid Embolic System (Onyx LES)P030004/S039 | Ev3 Neurovascular | PMA supplement | Oct 14, 2026 | FDA |
Explore the linked device profile
Other records with product code SGU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SQUID Liquid Embolic Agent (LEA)P250009/S001 | Balt USA, LLC | PMA supplement | Oct 16, 2026 | FDA |
SQUID Liquid Embolic Agent (LEA)P250009/S002 | Balt USA, LLC | PMA supplement | Sep 9, 2026 | FDA |
| Balt USA, LLC | PMA approval | Jan 30, 2026 | FDA | |
| Cerenovus, Inc. | PMA supplement | Dec 16, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ev3 Neurovascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9775 Toledo Way, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P030004/S035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





